Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

JOHNSON & JOHNSON (JNJ)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
 News SummaryMost relevantAll newsSector newsTweets
Most relevant news about JOHNSON & JOHNSON
08:01a THE POWER OF GLOBAL TALENT : Johnson & Johnson Joins the Coalition for the Ameri..
12/12 JOHNSON & JOHNSON : LSP closes second health economic fund at EUR 280M
12/12 JOHNSON & JOHNSON : DARZALEX® (daratumumab) Combination Regimen Significantly Im..
12/12 JOHNSON & JOHNSON : Motus GI Appoints Gary J. Pruden, Former Worldwide Chairman ..
12/12 Sanofi investors hungry for drug progress and deal news
12/11 JOHNSON & JOHNSON : New Data for DARZALEX® (daratumumab) Presented at ASH 2017 S..
12/09 JOHNSON & JOHNSON : Sustained Benefit in Patients with Relapsed/Refractory Mantl..
12/08 Edgewell touts creation of 140 new jobs at Dover plant
12/08 JOHNSON & JOHNSON : Woman suing j&j testifies she's in pain
12/07 JOHNSON & JOHNSON : Named to Glassdoor's 2018 List of Best Places to Work; The c..
12/07 U.K. unveils life sciences sector deal
12/07 BIOCENTURY - MANAGEMENT TRACKS : Sunesis, Vital
12/06 DOW MOVERS : Hd, jnj
12/06 GSK, other drugmakers bet on post-Brexit UK science
12/06DJBAYER : Johnson & Johnson Ordered to Pay $27.8 Million in Xarelto Lawsuit -Reute..
More most relevant news
All news about JOHNSON & JOHNSON
08:01a THE POWER OF GLOBAL TALENT : Johnson & Johnson Joins the Coalition for the Ameri..
05:13a MICROBOT MEDICAL : P. (Laxmin) Laxminarain Appointed to Microbot Medicals Board ..
12/12 JOHNSON & JOHNSON : Youth schooled on HIV/AIDS prevention and non-discrimination
12/12 JOHNSON & JOHNSON : LSP closes second health economic fund at EUR 280M
12/12 JOHNSON & JOHNSON : DARZALEX® (daratumumab) Combination Regimen Significantly Im..
12/12 JOHNSON & JOHNSON : Motus GI Appoints Gary J. Pruden, Former Worldwide Chairman ..
12/12 JOHNSON & JOHNSON : Joins HIV Campaign
12/12 Sanofi investors hungry for drug progress and deal news
12/11 JOHNSON & JOHNSON : New Data for DARZALEX® (daratumumab) Presented at ASH 2017 S..
12/11 JOHNSON & JOHNSON : Sustained Benefit in Patients With Relapsed/Refractory Mantl..
More news
Sector news : Pharmaceuticals - NEC
07:32aDJELI LILLY AND : Sees Modest Revenue Growth in 2018
07:16a SANOFI : CEO says M&A targets in oncology are 'very expensive'
06:13a REGENERON PHARMACEUTICALS : France's Sanofi pins hopes on new drugs after setbac..
04:09aDJPLANT IMPACT : Needs Extra GBP7 Million Funding by April, Hands up 'For Sale' Si..
03:55aDJSANOFI : to Begin at Least 10 Phase 3 Studies Over Next 12 Months
12:47a SANOFI : Did Sanofi, WHO ignore warning signals on dengue vaccine?
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
09:00a RETIREMENT STRATEGY : Applying My Simple Strategy To The Dividend King Retiremen..
03:03a I'm Sticking With CVS And Walgreens, My Last Two Losers
12/12 MCDONALD'S : Dividend Increase For Income And Good Total Return
12/12 Positive Market In 2017 - Cramer's Mad Money (12/11/17)
12/11 Johnson & Johnson files U.S. marketing application for expanded label use of ..
12/11 Where To Invest To Benefit From The Corporate Tax Cut
Financials ($)
Sales 2017 76 324 M
EBIT 2017 23 523 M
Net income 2017 16 391 M
Debt 2017 17 115 M
Yield 2017 2,35%
P/E ratio 2017 23,91
P/E ratio 2018 19,67
EV / Sales 2017 5,24x
EV / Sales 2018 4,84x
Capitalization 383 B
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 146 $
Spread / Average Target 2,1%
EPS Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Dominic J. Caruso Chief Financial Officer & Vice President
Paulus Stoffels Chief Scientific Officer & Executive VP
Charles O. Prince Independent Director
William David Perez Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON21.53%379 175
NOVARTIS12.01%218 773
PFIZER10.04%215 837
ROCHE HOLDING LTD.3.40%209 423
MERCK AND COMPANY-6.96%153 659
AMGEN19.97%128 363